BioCentury | Oct 19, 2018
Clinical News

Taris' TAR-302 reduces daily incontinence episodes by 75% in Phase Ib

...Taris Biomedical LLC (Lexington, Mass.) reported Phase Ib data in August showing that TAR-302 reduced mean...
...experiencing an average of more than five daily urge incontinence episodes. TAR-302 was well tolerated. TAR-302...
...daily micturition episodes and quality of life (QOL) Status: Phase Ib data Milestone: NA Brian Moy TAR-302, td-302 Taris...
BioCentury | Oct 28, 2015
Financial News

Taris Biomedical raises $32M series A

...next year of both TAR-200 to treat muscle invasive and non-muscle invasive bladder cancer and TAR-302...
Items per page:
1 - 2 of 2